Several members of the vitamin B -complex family are known to participate in the normal metabolism of homocysteine (Hcy). Leaving aside the genetic determinants of hyperhomocysteinemia (HHC), the deficiencies of these vitamins can also result in HHC. The situation of sustained and long standing HHC is likely to be prevalent in population groups with low/average socio-economic status, geriatric population and alcohol abusers. If not corrected by supplementation, these population groups certainly are more vulnerable to develop atherosclerosis (AS) and subsequently, cardiovascular disease (CVD). Hyperhomocysteinemia per se and/or HHC-induced oxidative stress result(s) in chronic chemical endothelial injury/ dysfunction, smooth muscle proliferation, prothrombotic state and oxidation of low density lipoproteins (LDL) leading to diverse cardiovascular complications. In the first decade of the new millennium, major research efforts would be directed towards understanding the basic mechanism of HHC-induced oxidative stress and the pathophysiology of HHC-induced CVD, culminating in the evolution of hitherto unknown therapeutic strategies such as nutriceuticals and oxidant-antidotes.
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two decades. Only recently, HHC has been linked with coronary artery disease, peripheral vascular disease, cerebrovascular disease as well as recurrent venous thrombosis and has been aptly labelled as the 'new cholesterol' (5-9). Though HHC has also been shown to be associated with neural tube defects, Alzheimer's disease and osteoporosis (10-12), the present review restricts to highlight the link between HHC and CVD, as well as the possible nutritional implications.
Homocysteine metabolism and determinants of hyperhomocysteinemia
Dietary methionine (Met), a sulphurcontaining essential amino acid, is the sole source of homocysteine (Hcy) in the body. Normally, Met is 'activated' to S-adenosyl methionine (SAM) which serves as the precursor for the synthesis of polyamines, compounds essential for the regulation of cell growth as well as ion transport (13) . More importantly, SAM follows the transmethylation pathway resulting in the formation of S-adenosyl homocysteine (SAH) and a variety of methylated derivatives of considerable biological significance. The subsequent hydrolysis of SAH yields Hcy and adenosine.
The methionine is regenerated by the transfer of a methyl group to Hcy from NS-methyltetrahydrofolic acid (NS-CH3-THFA) in the reaction catalyzed by methylcobalamine Ns-CH3-THFA : homocysteine methyl transferase (MTHMT), also called methionine synthase (MS) Actually, SAM initiates the reaction whereas Ns-CH3-THFA serves as the methyl donor for the synthesis of Met, completing the activated 'methyl cycle'. The latter is intimately linked with the 'folate cycle' and the enzymes of both these pathways are widely distributed. In addition, Hcy may be converted to Met in a reaction catalyzed by betaine : homocysteine methyl transferase (BHMT), which is, however, limited only to the liver and kidney(9-14).
Under conditions of Met excess or during an increased cellular demand for cysteine (Cys), the bulk of Hey is channelled into the 'transsulphuration pathway'. This route is confined only to the liver, Intracellular Hcy concentration is maintained at a low level by a specific cellular export mechanism (17) . The total plasma Hcy pool comprises of the protein bound form, mix6d disulphides, homocystine and free Hcy. The protein -bound form represents the predominant circulating component whereas the contribution of free Hcy to it, is minimal. However, the total Hcy pool is a mobile one as each of its component is freely exchangeable, depending on the redox state (18, 19) .
HOMOCYSTEINE~ ~e~eNE
Several vitamins, either as second substrates or as prosthetic groups, are essential in Hcy metabolism. Although some of them directly participate in the remethylation and/or transsulphuration pathways, others are indirectly linked through the enzymes involved in the 'folate cycle'. It is reasonable to argue that besides a disturbance in the Hcy metabolism itself, any abnormality in the metabolic pathway of the individual cofactors, could also be an important determinant of HHC. Such an abnormality may lie at the level of the quality of food, dk:jestion, absorption or enzymatic bioactivation of cofactors. Some aberrations in vitamin BI~ (cobalamine, cbl) metabolism associated with HHC illustrate this aspect -(i) chiC and cblD : deficiency of a reductase needed for the formation of methyl cobalamine and hydroxy cobalamine; (ii) cblE and cbIG : impaired activity of a particular component required to maintain a reduced form of cobalamine on the methyl transferase apoenzyme; and (iii) cblF : an impaired lysosomat efflux of cbl (20) .
Various physiological as well as pathological factors may contribute to HHC (Fig.3) . Until recently, a genetic deficiency and/or a mutation
Hyperhomocysteinemia-oxidative stressatherosclerosis-cardiovascular disease
Hyperhomocysteinemia promotes AS chiefly by causing-(i) endothelial cell (EC) dysfunction; (ii) smooth muscle celt (SMC) proliferation; (iii) disturbance in the coagulation system; and (iv) oxidation of low density lipoproteins (LDL), forming oxidized LDL(ox-LDL), a molecule endowed with marked proatherogenic characteristics (16, 35) . However, the aforesaid dysfunctions are also attributable to oxidatwe stress per se which is thought to underlie most of the basic pathogenic mechanisms put forward for AS (36) . Hence, it is reasonable to propose that the deleterious effects of HHC on the cardiovascular system could be mediated by oxidative stress (Fig. 4) .
Reactive oxygen species (ROSs, a term encompassing oxygen free radicals as well as some non-radicals) are constantly formed in the human body as the obligatory products of aerobic respiration. Because they are capable of inducing damage to cellular proteins, nucleic acids and biological membranes (if present in pathophysiological concentrations), evolution has endowed the body with a hierarchy of protective mechanisms, collectively termed as the antiox~dant defense system (AoDS). A pathological im6alance has been termed as oxidative stress which may make an important contribution to disease pathology (37) . Alternatively, increased oxidative stess may also be a result of the disease itself (38, 39) . Studies have shown that auto-oxidation of Hcy produces ROSs, specially in the presence of free transition metal ions (tM **). Homocysteine also contributes to the reduction of cystine to cysteine. In turn, the latter can not only be auto-oxidized to yield 02"-and H202, but also helps to oxidize glutathione (GSH) in the presence of tM," (40,41). Moreover, the ROSs produced as a result of autooxidation of Hcy and/or Cys could be responsible for the mobilization of iron from the cellular stores. The ROSs -induced endothelial injury may be important in the pathophysiology of AS. The injury may alter the functional characteristics of the endothetium such as its role as a permeability barrier, its nonthrombogenic character, its ability to release growth factors and vasoactive substances such as nitric oxide (NO), prostacyclin (PGI2), thromboxane ,% (TXA2) and endothelin-1, as well as its regeneration capacity. At the other extreme, endothelial injury may lead to EC dysfunction and endothelial retraction, exposing the underlying connective tissue or accumulated foam cells, such as macrophages that form the first and the ubiquitous lesions of AS, the fatty streak (46, 47) .
It is known that free iron is capable of exerting toxic effects through its ability to catalyze the formation of highly reactive hydroxyl radicals (OH)" via Fenton and Haber-Weiss reactions (42).

Since GSH is known as the 'redox battery' of the cell, any of the following factors leading to its depletion can profoundly affect the intracellular redox status -(i) GSH oxidation in the presence of Cys and tM,~*; (ii) GSH consumption in the process of detoxification of ROSs ; (iii) formation of Hcy-GSH mixed disulphide; and (iv) reduced Cys availability (GSH precursor) in cases of
Endothelial dysfunction apears to have immediate detrimental consequences as well as adverse long term effects, including vascular remodeling. Endothelial dysfunction is associated with impaired tissue perfusion particularly during stress and paradoxical vasoconstriction of large conduit vessels including the coronary arteries. These effects may cause or contribute to myocardial ischemia (48) . Several mechanisms may be involved in the development of endothelial dysfunction such as reduced synthesis and/or release of NO and enhanced oxidativ~ inactivation of NO after its release from EC by radicals, ox -LDL and high levels of Hc, y (46, 49) .
The ability of ROSs to alter EC function depends on their concentration, duration of exposure, the antioxidant status and their interaction with other bio-active compounds such as growth factors, cytokines, kinins, eicosanoids, aminoacids, nucleosides etc.(50-53) The mechanism of oxidantinduced EC dysfunction, though incompletely understood, may be due to the oxidant induced rise in intracellular ionic calcium ([Ca 2 "]j) by various mechanisms. This rise in [Ca2*], either alone or in combination with ROSs, is known to initiate a cascade of cellular events such as the activation of phospholipases (PL,%, PLC, PLD), protein kinases, endonucleases, proteases, expression of several immediate -early genes and last but not the least, the triggering of Ca 2.-influx possibly via the release and/or phosphorylation of a specific calcium influx factor (52, 53) . Collectively, these events lead to altered EC responses to agonists, enhanced permeability, increase in the prothrombotic mediators and reduced NO bio-availability, thereby jeopardizing the very survival of the cell.
A subnormal concentration of NO in the vascular microenvironment critically hampers the regulation of vasomotor tone. Moreover, NO is also important in modulating the local Hcy concentration as it forms a NO-Hcy adduct, thereby acting as a Hcy-buffer (16) . Thus, a low NO allows Hcy to exert its multiple deleterious effects. Certainly, the HHCinduced oxidative stress seems not only to initiate but also to perpetuate endothelial damage, establishing a vicious cycle of EC-dysfunction.
The ROSs and tMn** dependent formation of ox-LDL facilitates the recruitment of blood monocytes into the arterial wall, their differentiation into macrophages (Mac) and the subsequent Mac activation. It also promotes the procoagulant state, smooth muscle cell (SMC) proliferation and EC apoptosis (1, [54] [55] [56] [57] [58] . Further, ox-LDL activates a protein called peroxisome proliferator activated receptor-T-which enhances the transcription of the scavenger receptor gene, the protein product of which is CD36 that, in turn, mediates ox-LDL uptake into Mac, thus establishing a vicious cycle (59) .
Homocysteine leads to a prothrombotic state as a result of endothelial dysfunction at a variety of levels. It promotes platelet aggregation as well as the accumulation of thrombogenic molecules such as TX,% and vonWillebrand's factor, besides inhibiting fibrinolysis (60) (61) (62) . Alongwith platelet derived growth factor, it promotes SMC proliferation. These effects on the coagulation sy,~tem and SMC are due to the activation of critical transcription factors such as Nuclear Factor-Kappa B (NF-p(B) by ROSs. The activation of NF-~(B triggers the expression of cell adhesion molecules thereby contributing to the proliferative effects of Hcy on the vascular wall (63) .
Future Perspectives
The above discussion brings out the fact that the persistently raised level of Hcy is conducive for the development of oxidative stress. The latter, in turn, favours the pathogenesis of AS, the 'culprit' behind various forms of CVD, Conceivably, the concomitant presence of other risk factor(s) can amplify the entire scenario of AS and its sequelae. From the therapeutic point of view, two distinct facets emerge from the hyperhomocysteinemia-oxidative stress-atherosclerosis (H OSAS) hypothesis. Firstly, the limited availability of one or more co-factors such as folic acid, vitamin B~2, B 6, B2(?) and niacin(?)play an important role in the pathogenesis of HHC. Secondly, once HHC is established, the antioxidant status of the individual becomes the central deciding factor as far as the development of AS is concerned. The antioxidant micronutrients especially 13-carotene, vitamin E and vitamin C, if present in adequate concentrations, may counter the oxidant challenge.
The micronutrients known to be involved in the normal metabolism of Hcy, if required, can be used in supplemental form. For instance, some cases of HHC respond to vitamin B 6 supplemenation due to enhanced CI3S activity, in whom there is either a decreased affinity for the co-factor or an increased degradation of the mutant enzyme (20) . However, the supplementation of antioxidant vitamins ( the 'big three') needs to be practiced with caution since vitamin C in megadoses is known to behave paradoxically as a pro-oxidant, in the presence of tMn*', leading to the inactivation of vitamin B12 and/ or intrinsic factor thereby compromising the role of folic acid in Hcy metabolism (64) . Till clinical trials evaluate the role of vitamins to debridge the HHC-CVD bond and establish Hcy as a biomarker for the nutritional status a 'high nutriceutical diet' should be an integral part of the physician's prescription (65, 66) .
